Our innovative, customizable managed access, expanded access, compassionate use, and named patient programs are designed especially for clients that are patient-centered and that serve rare disease communities globally.
Combining proprietary technology, global expertise and best-in-class partners, a RareiTi managed access program is designed to provide the insights you need and the outcomes you want.
Connects you to those hard-to-reach communities, delivering on your commercial and strategic goals around the world.
International regulatory, reimbursement and operational expertise keeps you in compliance with local regulations.
The COVID-19 pandemic is having significant impact on clinical trials globally. Many trials face suspension or closure due to clinical priorities and the impact of social distancing and quarantine.
Clinical trial patients with a rare condition face great challenges; being part of a clinical trial when living with a rare condition can often be the only lifeline available, offering the chance to access novel therapies that could improve life enormously. During the pandemic, not being able to access novel therapies could have a major negative impact on health, disease progression and mortality. In addition, progress toward an approved therapy should not have to be completely stalled because of a lack of ability to collect relevant data.